Liquid biopsy is a minimally invasive diagnostic procedure that involves the analysis of DNA, RNA, proteins, or circulating tumor cells (CTCs) found in bodily fluids such as blood. It provides insights into cancer biology and patient-specific disease status without the need for tissue biopsies.
Liquid biopsies address the limitations of traditional tissue biopsy methods by providing non-invasive means for early detection, continuous monitoring, and real-time assessment of treatment response in cancer patients.
The process involves collecting a small volume of blood, which is then analyzed using advanced molecular techniques like next-generation sequencing, digital droplet PCR, or cell-free DNA analysis to detect genetic mutations, ctDNA (circulating tumor DNA), and CTCs. These analyses can identify the presence, type, and characteristics of cancer cells in the bloodstream.
Manufacturing involves developing and validating assays for detecting ctDNA and CTCs. This includes creating reagents, optimizing sample preparation protocols, and calibrating instruments to ensure consistent accuracy across different clinical settings.
The build process typically starts with the identification of specific biomarkers or genetic alterations associated with cancer. These are then used to design assays that can be integrated into existing laboratory workflows. Validation studies in controlled environments follow to confirm the reliability and reproducibility of the tests before they are deployed clinically.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.